Literature DB >> 20332439

Expression and role of phosphodiesterase 5 in human malignant melanoma cell line.

Taku Murata1, Kasumi Shimizu, Yoshihiro Watanabe, Hiroshi Morita, Motoko Sekida, Toshiro Tagawa.   

Abstract

BACKGROUND: Eleven phosphodiesterase (PDE) gene families (PDE1-11) have been identified, and some PDE isoforms are selectively expressed in various cell types. Previously, we reported PDE1, PDE3 and PDE4 expressions in human malignant melanoma cells. However, the expression and role of PDE5 in malignant melanoma cells is not clear. Therefore, we characterized PDE5 in human malignant melanoma MAA cells.
MATERIALS AND METHODS: PDE5 activity and PDE5A mRNA expression were investigated in MAA cells. The full open reading frames for human PDE5A1 were sequenced. Effects of PDE5 inhibitors on cell growth were determined by 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt (MTS) assays.
RESULTS: PDE5 activity and PDE5A1 mRNA expression were detected in MAA cells. The nucleotide sequence of PDE5A1 was identical to that of human PDE5A1, previously published. Two PDE5 inhibitors inhibited the growth of cells.
CONCLUSION: PDE5A1 mRNA is expressed and may play an important role in the growth of human malignant melanoma MAA cells.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20332439

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  9 in total

1.  Treating brain tumors with PDE4 inhibitors.

Authors:  Rajarshi Sengupta; Tao Sun; Nicole M Warrington; Joshua B Rubin
Journal:  Trends Pharmacol Sci       Date:  2011-03-28       Impact factor: 14.819

2.  RAF-isotype switching: from B to C through PDE.

Authors:  Eric Lau; Ze'ev Ronai
Journal:  Nat Struct Mol Biol       Date:  2011-05       Impact factor: 15.369

Review 3.  MC1R, the cAMP pathway, and the response to solar UV: extending the horizon beyond pigmentation.

Authors:  Jose C García-Borrón; Zalfa Abdel-Malek; Celia Jiménez-Cervantes
Journal:  Pigment Cell Melanoma Res       Date:  2014-05-30       Impact factor: 4.693

4.  Differential regulation of PDE5 expression in left and right ventricles of feline hypertrophy models.

Authors:  Xiaoyin Shan; Kenneth B Margulies
Journal:  PLoS One       Date:  2011-05-19       Impact factor: 3.240

Review 5.  Phosphodiesterase type 5 and cancers: progress and challenges.

Authors:  Ines Barone; Cinzia Giordano; Daniela Bonofiglio; Sebastiano Andò; Stefania Catalano
Journal:  Oncotarget       Date:  2017-10-12

Review 6.  Somatic mutations in solid tumors: a spectrum at the service of diagnostic armamentarium or an indecipherable puzzle? The morphological eyes looking for BRAF and somatic molecular detections on cyto-histological samples.

Authors:  Esther Diana Rossi; Maurizio Martini; Tommaso Bizzarro; Fernando Schmitt; Adhemar Longatto-Filho; Luigi Maria Larocca
Journal:  Oncotarget       Date:  2017-01-10

7.  Characterization of phosphodiesterase 2A in human malignant melanoma PMP cells.

Authors:  Hiroshi Morita; Taku Murata; Kasumi Shimizu; Kenya Okumura; Madoka Inui; Toshiro Tagawa
Journal:  Oncol Rep       Date:  2013-01-31       Impact factor: 3.906

8.  Prostate Cancer Cell Phenotypes Remain Stable Following PDE5 Inhibition in the Clinically Relevant Range.

Authors:  William Hankey; Benjamin Sunkel; Fuwen Yuan; Haiyan He; Jennifer M Thomas-Ahner; Zhong Chen; Steven K Clinton; Jiaoti Huang; Qianben Wang
Journal:  Transl Oncol       Date:  2020-05-23       Impact factor: 4.803

9.  No Causal Link between Phosphodiesterase Type 5 Inhibition and Melanoma.

Authors:  Jenny Z Wang; Stephanie Le; Claire Alexanian; Sucharita Boddu; Alexander Merleev; Alina Marusina; Emanual Maverakis
Journal:  World J Mens Health       Date:  2018-10-10       Impact factor: 5.400

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.